ストックスクリーナーアプリを入手
1.58
1.94%
0.03
プレマーケット:
1.58
前日終値:
$1.55
開ける：
$1.55
24時間の取引高:
5.79M
Relative Volume:
0.94
時価総額：
$490.57M
収益：
$160.01M
当期純損益:
$-546.38M
株価収益率:
-0.861
EPS:
-1.835
ネットキャッシュフロー:
$-118.92M
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
+17.91%
6か月 パフォーマンス:
-17.49%
1年 パフォーマンス:
+42.34%
1日の値動き範囲:
$1.50
$1.58
1週間の範囲:
$1.4201
$1.62
52週間の値動き範囲:
$0.8511
$2.73
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
名前
Pacific Biosciences Of California Inc
セクター
電話
650-521-8000
住所
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.58 | 490.57M | 160.01M | -546.38M | -118.92M | -1.835 |
ABT
Abbott Laboratories
|
87.17 | 151.83B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
295.25 | 113.08B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
77.79 | 99.87B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
55.98 | 83.21B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.91 | 47.80B | 6.30B | 1.07B | 1.34B | 1.8406 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-06 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2024-11-11 | ダウングレード | UBS | Buy → Neutral |
| 2024-06-03 | 再開されました | Jefferies | Buy |
| 2024-04-22 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-04-18 | ダウングレード | Goldman | Buy → Neutral |
| 2023-12-14 | 開始されました | Guggenheim | Neutral |
| 2023-12-14 | 開始されました | Stephens | Overweight |
| 2023-12-13 | 開始されました | Wolfe Research | Peer Perform |
| 2023-11-17 | アップグレード | UBS | Neutral → Buy |
| 2023-10-31 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | 開始されました | Bernstein | Outperform |
| 2023-07-05 | 再開されました | JP Morgan | Overweight |
| 2023-06-30 | 開始されました | Goldman | Buy |
| 2023-05-10 | 開始されました | Barclays | Equal Weight |
| 2023-03-31 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | 開始されました | UBS | Neutral |
| 2023-01-20 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | 開始されました | Scotiabank | Sector Outperform |
| 2022-01-21 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-01-06 | 再開されました | Piper Sandler | Neutral |
| 2021-10-15 | 再開されました | Cowen | Market Perform |
| 2021-09-27 | 開始されました | Canaccord Genuity | Buy |
| 2021-02-11 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-06-02 | 再開されました | Cantor Fitzgerald | Overweight |
| 2020-03-09 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-10-15 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | 開始されました | Cowen | Outperform |
| 2017-11-03 | ダウングレード | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | ダウングレード | CL King | Buy → Neutral |
| 2016-11-03 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2016-06-27 | 開始されました | CL King | Buy |
| 2016-04-15 | 開始されました | First Analysis Sec | Overweight |
| 2016-02-04 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2015-10-23 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | 開始されました | Cantor Fitzgerald | Buy |
| 2015-02-04 | 繰り返されました | Maxim Group | Buy |
| 2013-09-26 | 繰り返されました | Maxim Group | Buy |
| 2013-01-14 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Pacific Biosciences Of California Inc (PACB) 最新ニュース
PacBio (PACB) Q1 earnings report preview: What to look for - MSN
Pacific Biosciences of California pushes whole genome sequencing to transform newborn care - Traders Union
PacBio Pre-Q1 Analysis: Time to Buy, Hold or Sell the Stock Now? - Yahoo Finance
NGS-based RNA-seq Market Size Accelerating at 14.8% CAGR | By Key - openPR.com
AI powers deep genomics gains as Pacific Biosciences of California improves sequencing accuracy and reduces costs - Traders Union
MSN Money - MSN
Pacific Biosciences of California presents new AAV workflow to reduce partial snapback genomes - Traders Union
Pacific Biosciences of California (PACB) Projected to Post Quarterly Earnings on Thursday - MarketBeat
PACB Stock Price, Quote & Chart | PACIFIC BIOSCIENCES OF CALIF (NASDAQ:PACB) - ChartMill
Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know - Yahoo Finance
PacBio wins Basecamp Research deal for Trillion Gene Atlas initiative - MSN
Global Metagenomics Sequencing Market to Register Stunning Growth at a CAGR of ~13% by 2034 | DelveInsight - GlobeNewswire Inc.
PacBio and DNAstack collaborate on global HiFi genome network hub - MSN
Sequencing performance advances drive Pacific Biosciences of California to revamp SMRT Cell 101 resource - Traders Union
Here's why you should add PacBio stock to your portfolio now - MSN
Pacific Biosciences of California (PACB) laps the stock market: Here's why - MSN
Pacific Biosciences of California Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Pacific Biosciences of California Inc (PACB) News, Articles, Events & Latest Updates - Stocktwits
Pacific Biosciences of California launches PRISM San Diego, unveils SPRQ-Nx chemistry and Vega system - Traders Union
Pacific Biosciences of California (PACB) registers a bigger fall than the market: Important facts to note - MSN
[ARS] PACIFIC BIOSCIENCES OF CALIFORNIA, INC. SEC Filing - Stock Titan
PacBio (NASDAQ: PACB) plans 2026 virtual meeting, 16M-share equity plan boost - Stock Titan
Here's Why You Should Add PacBio Stock to Your Portfolio Now - MSN
Pacific Biosciences of California (PACB) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
HiFi sequencing technology from Pacific Biosciences of California brings biodiversity into sharper focus - Traders Union
PacBio & Lucid Genomics Partner to Boost Data Analysis, Stock Up - Yahoo Finance
Pacific Biosciences of California (NASDAQ:PACB) Stock Rating Lowered by Zacks Research - MarketBeat
PacBio (PACB) Partners with Lucid Genomics for Enhanced Data Ana - GuruFocus
Pacific Biosciences of California names Lucid Genomics as official partner for HiFi sequencing analysis - Traders Union
PacBio and Lucid Genomics Announce Compatibility Collaboration to Advance Tertiary Analysis for Long-Read Sequencing - marketscreener.com
PacBio and Lucid Genomics GmbH Announces Compatibility Collaboration to Advance Tertiary Analysis for Long-Read Sequencing - marketscreener.com
Farmer Michele sells Pacific Biosciences (PACB) shares for $4510 - Investing.com
Pacific Biosciences of California reveals unified approach to structural variant detection in cancer research - Traders Union
PacBio Stock (PACB) Opinions on Covaris FFPE Workflow Announcement - Quiver Quantitative
Sumitomo Mitsui Trust Group Inc. Lowers Position in Pacific Biosciences of California, Inc. $PACB - MarketBeat
Pacific Biosciences stock (US6932471010): Is long-read sequencing strong enough to unlock biotech up - AD HOC NEWS
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives Average Rating of "Hold" from Brokerages - MarketBeat
PacBio Stock Up on New FFPE Workflow Boosting Cancer Sequencing - TradingView
PacBio to Report First Quarter 2026 Financial Results on May 7, 2026 - Sahm
Pacific Biosciences of California compares leading long read sequencing technologies on accuracy and cost - Traders Union
May 7: PacBio investors get first-quarter results call and webcast - Stock Titan
Top Players and Competitive Dynamics in the Digital Genome Market - openPR.com
Pacific Biosciences of California (PACB) Stock Analysis: Exploring a 56% Potential Upside in Innovative Genomic Solutions - DirectorsTalk Interviews
PacBio and Covaris Announce Joint Workflow Enabling HiFi Long-Read Sequencing of FFPE Tumor Samples - Sahm
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today - Yahoo Finance
PacBio, Covaris develop workflow for FFPE tissue sequencing By Investing.com - Investing.com Canada
Pacific Biosciences Of California Inc (PACB) 財務データ
収益
当期純利益
現金流量
EPS
0.41%
0.93%
大文字化:
|
ボリューム (24 時間):